{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:27:26Z","timestamp":1783445246286,"version":"3.54.6"},"reference-count":29,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":3455,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objectives: Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher. Study Design: In this open-label, multicentre, phase III study, patients with locally advanced or metastatic medullary thyroid cancer were randomized to a patient outreach programme (outreach) or a standard AE monitoring schedule (vandetanib control) for 52 weeks. In addition to standard AE monitoring, patients in the outreach arm were contacted every 2 weeks by telephone\/during their clinic visit for specific AE questioning related to diarrhoea, nausea, vomiting, fatigue, headache and rash. Patients received vandetanib at 200 or 300 mg\/day, depending on the creatinine levels at screening. Results: Altogether, 205 patients were randomized (outreach, n = 103; vandetanib control, n = 102). This study did not meet its primary objective; the mean percentage of time patients experienced at least one AE of grade 2 or higher was higher for the outreach group (51.65%) than for the vandetanib control group (45.19%); the difference was not statistically significant (t statistic: 1.29; 95% CI -3.44 to 16.37%; p = 0.199). The most frequently reported AEs were diarrhoea (56.9% for the outreach group vs. 46.6% for the vandetanib controls), hypertension (36.3 vs. 31.1%), rash (25.5 vs. 24.3%) and nausea (25.5% vs. 18.4%), and the most frequently reported AEs of grade 2 or higher were hypertension (33.3 vs. 23.3%), diarrhoea (26.5 vs. 24.3%) and dermatitis acneiform (11.8 vs. 9.7%). Conclusions: Additional outreach to patients treated with vandetanib had no impact on the rate or severity of AEs compared to the standard AE monitoring schedule. AEs were consistent with the known safety profile of vandetanib.<\/jats:p>","DOI":"10.1159\/000448919","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T17:02:47Z","timestamp":1473440567000},"page":"187-194","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":11,"title":["Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer"],"prefix":"10.1530","volume":"5","author":[{"given":"Lars","family":"Bastholt","sequence":"first","affiliation":[{"name":"1Department of Oncology R, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kreissl","sequence":"additional","affiliation":[{"name":"2Department of Nuclear Medicine, Augsburg Hospital, Augsburg"},{"name":"3Department of Nuclear Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"4Department of Endocrinology and Metabolism, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Maia","sequence":"additional","affiliation":[{"name":"5Servi\u00e7o de Endocrinologia, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D.","family":"Locati","sequence":"additional","affiliation":[{"name":"7Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Maciel","sequence":"additional","affiliation":[{"name":"6Hospital das Cl\u00ednicas de Ribeir\u0103o Preto, Ribeir\u0103o Preto, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"9Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N.","family":"Heller","sequence":"additional","affiliation":[{"name":"10AstraZeneca, Gaithersburg, Md., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Webster","sequence":"additional","affiliation":[{"name":"11AstraZeneca, Macclesfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9257","authenticated-orcid":false,"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"8Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2016,9,10]]},"reference":[{"key":"2026070712472943000_ref1","doi-asserted-by":"crossref","unstructured":"Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BA: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.10.1038\/363458a08099202","DOI":"10.1038\/363458a0"},{"key":"2026070712472943000_ref2","doi-asserted-by":"crossref","unstructured":"Lakhani VT, You YN, Wells SA: The multiple endocrine neoplasia syndromes. Annu Rev Med 2007;58:253-265.10.1146\/annurev.med.58.100305.11530317037976","DOI":"10.1146\/annurev.med.58.100305.115303"},{"key":"2026070712472943000_ref3","doi-asserted-by":"crossref","unstructured":"Martins RG, Rajendran JG, Capell P, Byrd DR, Mankoff DA: Medullary thyroid cancer: options for systemic therapy of metastatic disease? J Clin Oncol 2006;24:1653-1655.10.1200\/JCO.2005.05.410616549818","DOI":"10.1200\/JCO.2005.05.4106"},{"key":"2026070712472943000_ref4","doi-asserted-by":"crossref","unstructured":"Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.10.1089\/thy.2008.040319469690","DOI":"10.1089\/thy.2008.0403"},{"key":"2026070712472943000_ref5","doi-asserted-by":"crossref","unstructured":"Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.10.1093\/hmg\/2.7.8518103403","DOI":"10.1093\/hmg\/2.7.851"},{"key":"2026070712472943000_ref6","doi-asserted-by":"crossref","unstructured":"Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H: Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994;91:1579-1583.10.1073\/pnas.91.4.15797906417","DOI":"10.1073\/pnas.91.4.1579"},{"key":"2026070712472943000_ref7","doi-asserted-by":"crossref","unstructured":"Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996;44:249-257.10.1046\/j.1365-2265.1996.681503.x8729519","DOI":"10.1046\/j.1365-2265.1996.681503.x"},{"key":"2026070712472943000_ref8","doi-asserted-by":"crossref","unstructured":"Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A: Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-687.10.1210\/jc.2007-171418073307","DOI":"10.1210\/jc.2007-1714"},{"key":"2026070712472943000_ref9","unstructured":"Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.12499271"},{"key":"2026070712472943000_ref10","doi-asserted-by":"crossref","unstructured":"Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M: The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 2011;18:1-11.10.1677\/ERC-09-029220943719","DOI":"10.1677\/ERC-09-0292"},{"key":"2026070712472943000_ref11","doi-asserted-by":"crossref","unstructured":"Rodriguez-Antona C, Pallares J, Montero-Conde C, Inglada-Perez L, Castelblanco E, Landa I, Leskela S, Leandro-Garcia LJ, Lopez-Jimenez E, Leton R, Cascon A, Lerma E, Martin MC, Carralero MC, Mauricio D, Cigudosa JC, Matias-Guiu X, Robledo M: Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010;17:7-16.10.1677\/ERC-08-030419776290","DOI":"10.1677\/ERC-08-0304"},{"key":"2026070712472943000_ref12","doi-asserted-by":"crossref","unstructured":"Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M: New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2008;4:22-32.10.1038\/ncpendmet071718084343","DOI":"10.1038\/ncpendmet0717"},{"key":"2026070712472943000_ref13","unstructured":"Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655.12183421"},{"key":"2026070712472943000_ref14","unstructured":"AstraZeneca: Caprelsa (vandetanib) tablets - prescribing information. 2011."},{"key":"2026070712472943000_ref15","doi-asserted-by":"crossref","unstructured":"Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-1397.10.1093\/annonc\/mdi24715905307","DOI":"10.1093\/annonc\/mdi247"},{"key":"2026070712472943000_ref16","doi-asserted-by":"crossref","unstructured":"Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai S, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-1009.10.1016\/S1556-0864(15)31634-817409986","DOI":"10.1097\/01243894-200611000-00014"},{"key":"2026070712472943000_ref17","doi-asserted-by":"crossref","unstructured":"Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-772.10.1200\/JCO.2009.23.660420065189","DOI":"10.1200\/JCO.2009.23.6604"},{"key":"2026070712472943000_ref18","doi-asserted-by":"crossref","unstructured":"Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R: Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-2671.10.1210\/jc.2009-246120371662","DOI":"10.1210\/jc.2009-2461"},{"key":"2026070712472943000_ref19","doi-asserted-by":"crossref","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Vasselli JR, Read J, Schlumberger M: Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010;28:15S.","DOI":"10.1200\/jco.2010.28.15_suppl.5503"},{"key":"2026070712472943000_ref20","doi-asserted-by":"crossref","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141.10.1200\/JCO.2011.35.504022025146","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"2026070712472943000_ref21","doi-asserted-by":"crossref","unstructured":"Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, Schlumberger M, Tolstrup LK, Zamorano JL, Capdevila J: Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther 2013;30:945-966.10.1007\/s12325-013-0069-524249433","DOI":"10.1007\/s12325-013-0069-5"},{"key":"2026070712472943000_ref22","unstructured":"World Medical Association: Declaration of Helsinki - ethical principles for medical research involving human subjects. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html."},{"key":"2026070712472943000_ref23","unstructured":"AstraZeneca: Global policy: bioethics. 2015. http:\/\/www.astrazeneca.com\/Responsibility\/Code-policies-standards\/Our-global-policies."},{"key":"2026070712472943000_ref24","doi-asserted-by":"crossref","unstructured":"Basch E: The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362:865-869.10.1056\/NEJMp091149420220181","DOI":"10.1056\/NEJMp0911494"},{"key":"2026070712472943000_ref25","doi-asserted-by":"crossref","unstructured":"Wernicke JF, Faries D, Milton D, Weyrauch K: Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Saf 2005;28:1057-1063.10.2165\/00002018-200528110-0000616231957","DOI":"10.2165\/00002018-200528110-00006"},{"key":"2026070712472943000_ref26","doi-asserted-by":"crossref","unstructured":"Molokhia M, Tanna S, Bell D: Improving reporting of adverse drug reactions: systematic review. Clin Epidemiol 2009;1:75-92.10.2147\/CLEP.S477520865089","DOI":"10.2147\/CLEP.S4775"},{"key":"2026070712472943000_ref27","doi-asserted-by":"crossref","unstructured":"Langmuir PB, Yver A: Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther 2012;91:71-80.10.1038\/clpt.2011.27222158569","DOI":"10.1038\/clpt.2011.272"},{"key":"2026070712472943000_ref28","doi-asserted-by":"crossref","unstructured":"Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G: Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50:203-218.10.1053\/j.ajkd.2007.04.02517660022","DOI":"10.1053\/j.ajkd.2007.04.025"},{"key":"2026070712472943000_ref29","doi-asserted-by":"crossref","unstructured":"Herbst RS: Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006;8(suppl 1):S23-S30.10.3816\/CLC.2006.s.01017239287","DOI":"10.3816\/CLC.2006.s.010"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/448919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/5\/3\/187\/29652\/etj448919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/5\/3\/187\/29652\/etj448919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:10:12Z","timestamp":1783444212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/5\/3\/187\/4007\/Effect-of-an-Outreach-Programme-on-Vandetanib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000448919","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}